Effect of lamivudine in HBeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level

Table 2 Multivariate Cox regression analysis of factors associated with HBeAg loss.

Variables	Relative risk	95% CI	P
Age <30 (yr)	1.0
≥30 (yr)	1.995	0.236-16.898	0.526
Gender male	1.0
female	5.247	0.294-93.594	0.260
ALT <200 IU/L	1.0
≥200 IU/L	13.158	1.153-142.857	0.038
HBV DNA (LGE/mL)	0.751	0.479-1.178	0.212
Core promoter Wild	1.0
Mutant	0.944	0.234-3.817	0.936
Precore Wild	1.0
Mutant	0.749	0.050-11.236	0.834
Lamivudine Untreated	1.0
Treated	9.826	0.765-126.290	0.079